High-calorie diet has been shown to impair learning ability and hippocampal synaptic plasticity in rodents. This study examined effects of daily treatment with the glucagon-like peptide-1 mimetic, exendin-4, on cognitive function and hippocampal synaptic plasticity in a model of diet-induced obesity, which exhibits compromised cognitive performance. Mice fed a high-fat diet were treated with exendin-4 (25 nmol kg À1 bodyweight; twice daily) or saline vehicle (0.9% (w/v) NaCl) over 21 days. In addition to improving metabolic control, exendin-4-treated mice exhibited a marked increase in recognition index highlighting improved learning and memory. High-fat diet resulted in the elimination of in vivo electrophysiological long-term potentiation, which was rescued following exendin-4 treatment. This study shows that exendin-4 therapy improves cognitive function and ameliorates impaired hippocampal synaptic plasticity in dietary-induced obesity.
Introduction
Exendin-4 is an enzyme-resistant glucagon-like peptide-1 (GLP-1) mimetic, which exhibits a wide spectrum of actions that underlie its clinical effectiveness in the treatment of type 2 diabetes. 1 Interestingly, GLP-1 receptors are expressed within the neocortex and hippocampal regions of the brain, which are key areas responsible for modulating learning and memory processes. 2 Indeed, mice with targeted deletion of the GLP-1 receptor exhibit demonstrable impairments in synaptic plasticity and cognitive performance whereas over-expression of GLP-1 in the hippocampus enhanced spatial learning. 3, 4 In addition, GLP-1 has neuroprotective properties, protecting neurons from kainite-induced neurotoxicity and reducing hippocampal neuronal apoptosis. 3, 5 A recent study from our laboratory has shown that GLP-1 directly modulates neurotransmitter release and long-term potentiation (LTP) formation, and protects synapses from detrimental effects of b-amyloid fragments on LTP formation. 6 Together with the observation that GLP-1 and derivative molecules cross the blood-brain-barrier when administered peripherally, 7 the primary aim of this study was to investigate whether the established GLP-1 mimetic, exendin-4, also improved parameters associated with cognitive function. Exendin-4 was administered to a mouse model of dietary-induced obesity, which exhibits compromised cognitive performance. 8 Cognitive function
was assessed through object recognition test and electrophysiological in vivo hippocampal synaptic plasticity by means of LTP. Object recognition test Two identical objects (two marbles, 2.5 cm diameter; or two dice, 1.2 cm side length) randomized between groups were placed in the centre of an arena (58 cm diameter, 38 cm high) for 5 min with a video camera positioned above the arena. 4 Four hours after initial exposure (acquisition phase), one of the two objects was replaced with a novel object (a marble or dice) and time spent exploring the two objects determined during a 10 min trial phase. A computerized tracking program (Biosignals, New York, NY, USA) analysed visits within a specified area (2.5 cm radius) around each object. Time spent exploring the novel object (B) was expressed as recognition index (RI) which is time (t) spent exploring the novel object divided by time spent exploring both objects (A þ B) times 10 [4] . RI B ¼ tB/t(A þ B) Â 100 normalizes all data for statistical comparison.
Materials and methods
In vivo electrophysiological recording of LTP in area CA1 of the hippocampus Animals (n ¼ 6) anaesthetized with urethane (ethyl carbamate, 1.8 g kg
À1
, i.p.) had their skulls exposed and three holes (0.8 mm diameter) drilled. Teflon-coated Tungsten electrodes (Bilaney Consultants Ltd, Kent, UK) were implanted: 1.2 mm posterior, 1.5 mm lateral to midline for recording electrode; 2.5 mm posterior to bregma, 2 mm lateral to midline for stimulating electrode. Electrodes were slowly lowered through the cortex and upper layers of the hippocampus into CA1 region until the appearance of a negative deflecting excitatory postsynaptic potential (EPSP) with a latency of B10 ms was observed. Recordings of field EPSPs (PowerLab, ADInstruments Ltd, Chalgrove, UK) were made from stratum radiatum in CA1 region of the right hippocampal hemisphere in response to stimulation of the Schaffer collateral/commissural pathway. A constant current stimulus isolation unit (Neurolog, London, UK) and data acquisition system were triggered simultaneously to record all events. Sampling speed was set at 20 kHz for recordings of fEPSPs. The high-frequency stimulation protocol for inducing LTP consisted of 3 trains of 200 stimuli; inter-stimulus interval 5 ms (200 Hz); and inter-train interval 2 s. Stimulation intensity was 70% of maximum fEPSP as analysed by input-output correlation. LTP was measured as percentage of baseline fEPSP slope recorded over 15 min period before application of highfrequency stimulation. This value was taken as 100% of EPSP slope and recorded values normalized to this baseline value.
Biochemical and statistical analyses
Blood samples were collected from tail vein of conscious mice and immediately centrifuged (30 s at 13 000 g). Plasma glucose was assayed using a Beckman Glucose Analyzer II and insulin determined by radioimmunoassay. 9 Data were analysed using repeated measures one-way or two-way ANOVA with Bonferroni post hoc tests or repeated measure two-tailed t-tests. Data are means±s.e. Po0.05 was considered significant.
Results
Daily administration of exendin-4 for 21 days had no significant effect on body weight; however, energy intake was reduced in exendin-4-treated mice compared with saline-treated high-fat controls (1.2-fold, Po0.001; Table 1 ). Non-fasting plasma glucose concentrations were significantly decreased (1.7-fold, Po0.05) and plasma insulin concentrations increased (1.6-fold, Po0.001) ( Table 1) . Similarly, exendin-4-treated mice showed improved glucose tolerance (1.6-fold; Po0.05) and enhanced glucose-mediated plasma insulin responses (1.8-fold; Po0.05) compared with saline-treated high-fat controls (Table 1) . 
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As shown in Figure 1a , no significant difference was observed in the RI between any of the treatment groups during the acquisition phase. Furthermore, groups did not show a bias for one object towards another as indicated by an RI value close to 50%. During the test phase 4 h later, exendin-4-treated mice showed a significant increase (1.4-fold; Po0.05) in RI to around 70%, highlighting a preference to explore the novel object (Figure 1b) . Importantly, saline-treated high-fat mice did not show a bias for the novel vs familiar object (RI value close to 50% as in acquisition phase).
LTP induced by high-frequency stimulation in area CA1 of the hippocampus was completely abolished in saline-treated high-fat mice (Figure 1c ). Daily treatment with exendin-4 for 21 days ameliorated the detrimental effects of high-fat diet on LTP (two-way ANOVA: group factor F 1,10 ¼ 16.3; Po0.005; time factor F 1,119 ¼ 714, Po0.0001; interaction between factors not significant; Figure 1c) . Furthermore, high-fat fed mice treated with exendin-4 showed similar LTP to that observed for healthy age-matched lean controls (two-way ANOVA not significant). A difference was found between saline-treated high-fat mice and lean controls (group factor F 1,10 ¼ 18.7; Po0.001; time factor F 1,119 ¼ 655; Po0.001). Interaction between factors was not significant.
Discussion
Impairments in cerebral insulin signalling result in markedly impaired hippocampal synaptic neurotransmission and cognitive function. 10 Furthermore, high-calorie diet impairs learning ability, decreases hippocampal dendritic spine density and impairs LTP at Schaffer collateral-CA1 synapses. 8 As GLP-1 crosses the blood-brain barrier 7 and directly modulates neurotransmitter release and LTP, 6 we assessed effects of peripheral exendin-4 therapy on cognitive function in a mouse model of diet-induced obesity, which exhibits compromised cognitive performance. As expected, twice-daily administration of exendin-4 effectively improved metabolic control, glucose homeostasis and cognitive function in high-fat mice in accordance with 11 however, further studies are necessary to confirm this. However, the object recognition test clearly showed that mice fed a high-fat diet exhibited notable impairments in cognitive performance as they failed to discriminate between the familiar and the novel object. In contrast, high-fat fed mice treated with exendin-4 spent significantly more time exploring the novel object, indicating a significant improvement in cognitive function. Interestingly, the recognition index for the exendin-4-treated high-fat mice was similar to that observed for healthy agematched lean controls, further highlighting that the cognitive decline arising from the high-fat diet had been reversed. LTP examines the strength of synaptic connections between hippocampal neurons, and as such, provides a useful handle on information storage at the cellular level. In this study, it is clear that LTP induction and maintenance is severely compromised in mice fed a high-fat diet, indicative of adverse effects on cognitive function. 8 In comparison, when high-fat fed mice were treated with exendin-4 for 21 days, LTP was rescued and observed to follow a similar pattern to that of healthy lean controls. The data presented in this preliminary study clearly show a beneficial effect of exendin-4 treatment on cognitive function and synaptic plasticity in diet-induced obesity. In normal animals, studies have shown that exendin-4 and other GLP-1 mimetics have very little effect on general behaviour. Thus, exendin-4 has no effect on basic activity such as anxiety, motor or exploratory activity in an open field test. 12 In a water maze test, exendin-4 and related GLP-1 peptides have been shown to slightly enhance learning abilities in normal animals (compared with saline controls) at similar doses to those used in this study. 3, 12, 13 Furthermore, GLP-1 peptides do exhibit moderate facilitating effects on LTP in the hippocampus of normal animals. 6 The precise mechanisms underlying these positive actions in the obese state are still unclear and additional studies are necessary. Nevertheless, though it is likely that improvements in cognitive function after exendin-4 therapy could be due to an indirect effect of the peptide on improving metabolic control, direct effects mediated through activation of GLP-1 receptors in the brain cannot be ignored. Further studies are required to address these issues and any possible related implications of the increasing use of GLP-1 mimetics for the treatment of type 2 diabetes in man.
